MASSACHUSETTS GENERAL HOSPITAL
Immuno-Cell Therapy for Brain Tumors
Immuno-Cell Therapy for Brain Tumors is a funding opportunity from MASSACHUSETTS GENERAL HOSPITAL, up to 597585, closing December 31, 2026.
Dec 31, 2026
(153d left)Overview
Abstract Glioblastoma (GBM) comprises 50% of all brain tumors in adults and is the most malignant form with a 5-year patient survival rate of 3.3%. Standard-of-care treatment involves maximal surgical resection followed by radiation and chemotherapy (temozolomide); however, as the poor survival rate indicates, these…